Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic

Abstract Introduction: The aim of this study was to characterize the use of tocilizumab in a hospital. Method: Retrospective cohort study including adult SARS-CoV-2 infected inpatients with moderately severe infection (PaO2/FiO2 < 300). ORs for mortality and treatment success were calculated. Results: The tocilizumab group (n=18), presented 5 days of symptoms vs 7 days in the untreated group (n=71). Minimum PaO2/FiO2 was 147.5 (95%CI: 116.7 to 194.0) vs 255.6 (95%CI: 320.7 to 452.4) (p=0.01). No significant differences were found between the two groups concerning survival (OR=1.22; 95%CI: 0.38 to 3.92), nor treatment success (OR=0.46; 95%CI: 0.16 to 1.33). After adjusting for age, sex and total corticosteroid dose, OR for success was 0.18 (95%CI: 0.03 to 0.96), while mortality was not significant. Conclusions: The use of tocilizumab in moderately severe hospitalized patients could decrease the hyperinflammatory state preventing disease progression.

Bibliographic Details

Main Authors:	Carrera-Hueso,Francisco Javier, Alvarez-Arroyo,Laura, Robustillo-Villarino,Montse, Pérez-Olaso,Óscar, El-Qutob,David, Martínez-Martínez,Fernando
Format:	Digital revista
Language:	English
Published:	Universidad de Granada 2022
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-98942022000200166
Tags:	Add Tag No Tags, Be the first to tag this record!